“There is a lot of news out today in health care, and I expect more news throughout the week -- JPMorgan's health care conference begins today, and nearly every major player will make a presentation. Celgene (CELG), one of the stocks I own, will be speaking at the conference today. I expect management to issue conservative guidance relative to expectations due to currency issues, and if the shares are weak, I will be a buyer -- especially under $48. Fundamentals remains strong with its flagship compound Revlimid, and it continues to dominate the cancer market. There are a number of other indications for Revlimid, most notably non-Hodgkin's lymphoma -- if approved, this could add another leg of growth to the company. Separately, Abbott (ABT) announced that it is acquiring Advanced Medical Optics (EYE) for $2.8 billion, or $22 a share. The company said it will be accretive to 2010 and neutral to 2009 estimates. Abbott also reiterated 2008 earnings and officially announced its 2009 estimates, which are at the high end of the current expectations (it guided to $3.65-$3.70 vs. the Street at $3.66). Advanced Medical Optics is the global leader in ophthalmic care -- it has the No. 1 market share in laser vision correction, the No. 2 position in cataracts and is the third-largest company in products for contact lens care. Abbott will become the global leader in vision care overnight with this deal. The acquisition further strengthens the company's medical device business and provides new opportunities for growth given the powerful demographic trends for advanced vision care across around the world. The demographics are powerful -- 60% of people over 60 years old have cataracts, and that population group is expected to grow from 700 million to 1 billion over the next decade. There is real growth here. In other health care news, Roche is upping its bid for Genetech (DNA), Medtronic is acquiring a privately held medical technology firm called Ablation Frontiers, Sequenom (SQNM) has made a hostile bid for Exact Sciences (EXAS), and General Electric's (GE) health care division announced a partnership with cosmetic/reconstructive surgery company Cytori Therapeutics. I've written several times that I believe 2009 will be the year for mergers and acquisitions in the health care industry because the larger companies need to continue to build their pipelines due to patent expiration issues. Last week, Pfizer (PFE) announced it will explore acquisitions to offset Lipitor generic competition beginning in 2012. So today's news isn't entirely a surprise, but rather a sign of more to come.

From a recent Mad Money show: "I like Kraft for the long term. There are so many of their products that are good trade downs. Every time that one pulls back, I want you to buy more."

From a recent Mad Money show: "I think this is such an Obama play I'm surprised people aren't taking notice. The only company that makes money from upgrading the electrical system is Quanta."

From a recent Mad Money show: "I don't trust the dividend; that's a red flag. I think if you want a natural gas company, you want Anadarko Petroleum (APC). That's the best."

From a recent Mad Money show: "No! That whole drug store business has gone to heck. I want you to sell, sell, sell."

From a recent Mad Money show: "Oh come on, an expensive fast food company when McDonald's (MCD) is trading this low? I want you to go buy McDonalds."

From a recent Mad Money show: "This is supposed to be recession resistant, but I don't trust the business model. I want to stay away from that one."

From a recent Mad Money show: "No, no. The quarter's going to be bad. I think they're going to have a disappointing quarter and you're going to be able to buy it lower."